SEATTLE - April 26, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has released a new line of TransCam™ photo identification solutions tailored to the particular needs of the identification and security market.
The ID security and access control industries have unique requirements for image capture systems. Cameras must be high-quality and low-cost, produce quality images in all lighting conditions, and able to interface with specialized badge design software for instant creation and issuance of identification credentials. These systems must also be designed for portable use in multiple locations such as a school district, and for permanent installation at a central location, such as a corporate security office. TransTech Systems has recognized these needs and designed two unique camera kits under the TransCam™ brand name. These two unique camera kits are available for immediate distribution.
The TransCam WDM camera kit is designed for portability and includes both a top-of-the-line 8 megapixel high-definition compact camera for capturing crisp and vibrant images of the subject, and TWAIN-driver software solution. The camera can be controlled directly from the user's computer to capture the perfect photo, and the integrated face-finder combined with auto-crop ensures that ID badges are created quickly and professionally.
The TransCam ACK camera kit is designed for high-volume badge issuance. This kit combines a versatile camera from a leading camera manufacturer with a unique TWAIN-driver software solution that provides the user direct control of camera features such as zoom and focus without leaving the workstation to make adjustments.
The TransCam™ camera kits are compatible with the most popular ID Badging solutions in the industry. Deluxe versions of the TransCam kits are also available, offering a high-quality blue/gray reversible backdrop and full-size tripod for use with the camera's integrated tripod mount.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclosure and Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs.
(1500 per month and $five thousand per month in restricted 144 shares)
Tuesday, April 26, 2011
Thursday, April 21, 2011
Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Clarifies News Report
SAN DIEGO - April 21, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) disclosed that it was the subject of an ABC affiliate station news story that included discussion of the company's proposed strategy to reduce the occurrence of sepsis in wounded military personnel. As previously disclosed, the company submitted a contract response on April 1, 2011 to a Broad Agency Announcement (BAA) entitled Dialysis Like Therapeutics (DLT). In the submission, company proposed multiple capabilities including the development of dialysis-like therapy that would address the objectives of the DLT program. The company wishes to clarify that there is no assurance it will be invited to participate in the DLT program and that battlefield deployment of such a device is not feasible in the near future as suggested in the ABC affiliate news story. However, the company does believe that successful clinical outcomes in treating Hepatitis-C (HCV) infected patients with its Hemopurifier� technology does offer the potential for an early commercialization pathway of its Hemopurifier� in India. The company appreciates the coverage by the ABC news affiliate which unfortunately confused the potential commercialization timeline of our Hemopurifier� with the device proposed to be developed in our DLT response.
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
- Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
- Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
- Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
- Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Security Stocks; UPSG (TSX-V: UZZ) MOVES INTO EASTERN CANADA
EDMONTON - April 20, 2011 (InvestorIdeas.com Newswire) - F.V.Ramsoondar, Chief Executive Officer of United Protection Security Group Inc. (UPSG or the Company), (TSX-V:UZZ) announces the appointment of Don Dassanayake as Senior Vice President of Operations and Business Development for Eastern Canada.
Mr. Ramsoondar further states: "Don's appointment is the first step in a national growth strategy that will be deployed in 2011 and beyond. Our objective is to grow the Company into one of the largest national security service providers in Canada over the next five years."
Don was the Chief Financial Officer of the Canadian division of the world's largest security company. He was also a senior member of the executive management and acquisition teams and contributed to the company growing its Canadian operations from $23 million to $200 million in annual revenues. During his tenure he was involved with closing several successful acquisitions.
Don Dassanayake joins UPSG with over 20 years experience in the security industry. He is a member of the Chartered Institute of Management Accountants and past member of the Institute of Data Processing Management in the United Kingdom.
Don's mandate is to build UPSG's Eastern Canada operations through acquisitions and future organic growth.
Stock Awareness Activities
To find out more about United Protection Security Group Inc. (TSX-V:UZZ), visit our website at www.unitedprotection.com. To join the 'request for information', go to the web page www.unitedprotection.com and click the tab 'request information' and follow the prompts. You may also email Investor Relations at: iruzz@unitedprotection.com.
Statements in this press release other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, are forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks related to business development and retention, and risks related to the current economic and credit conditions. As a result, actual results may vary materially from those described in the forward-looking statements.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein.
Disclosure: UZZ is a paid advertising client on Investorideas.com and our defense portals.
Mr. Ramsoondar further states: "Don's appointment is the first step in a national growth strategy that will be deployed in 2011 and beyond. Our objective is to grow the Company into one of the largest national security service providers in Canada over the next five years."
Don was the Chief Financial Officer of the Canadian division of the world's largest security company. He was also a senior member of the executive management and acquisition teams and contributed to the company growing its Canadian operations from $23 million to $200 million in annual revenues. During his tenure he was involved with closing several successful acquisitions.
Don Dassanayake joins UPSG with over 20 years experience in the security industry. He is a member of the Chartered Institute of Management Accountants and past member of the Institute of Data Processing Management in the United Kingdom.
Don's mandate is to build UPSG's Eastern Canada operations through acquisitions and future organic growth.
Stock Awareness Activities
To find out more about United Protection Security Group Inc. (TSX-V:UZZ), visit our website at www.unitedprotection.com. To join the 'request for information', go to the web page www.unitedprotection.com and click the tab 'request information' and follow the prompts. You may also email Investor Relations at: iruzz@unitedprotection.com.
Statements in this press release other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, are forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks related to business development and retention, and risks related to the current economic and credit conditions. As a result, actual results may vary materially from those described in the forward-looking statements.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein.
Disclosure: UZZ is a paid advertising client on Investorideas.com and our defense portals.
Published at the Investor Ideas Newswire
Wednesday, April 20, 2011
Biotech/Biodefense Stock News; ABC News Reports on Aethlon Medical (OTCBB: AEMD)
SAN DIEGO - April 20, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it is the subject of an ABC news story that can be accessed online at: http://www.10news.com/news/27605561/detail.html
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® inIndia
as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
- Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
- Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
- Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
- Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Biotech/Biodefense Stock News; RedChip Research Issues Research Update on Aethlon Medical (OTCBB: AEMD)
ORLANDO, Fla. - April 20, 2011 (Investorideas.com newswire) RedChip Research(TM), a division of RedChip Companies, Inc., today announced it has issued a research update on Aethlon Medical, Inc. (OTCBB: AEMD), a company developing therapeutic filtration devices to address infectious disease and cancer.
To receive a complimentary copy of the RedChip Research Report for AEMD, please visit: http://www.redchip.com/about/aboutmain.asp?rid=357
To learn more about Aethlon Medical, Inc. visit http://www.redchip.com/visibility/investor.asp?symbol=AEMD
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida; with affiliate offices in Beijing, China; Paris, France; and Seoul, Korea. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(TM), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap TV(TM), Shareholder Intelligence, Social Media and Blogging Services, Webcasts, and RedChip Radio(TM). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp.
"Discovering Tomorrow's Blue Chips Today"(TM)
The RedChip Companies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2761
Disclosure
None of the reports issued by RedChip Companies, Inc., constitutes a recommendation for any investor to purchase or sell any particular security nor do they constitute investment advice. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Information contained in the research reports is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. Aethlon Medical, Inc. (AEMD) is a client of RedChip Companies, Inc. and of RedChip Visibility, a division of RedChip Companies. AEMD has agreed to pay RedChip Companies, Inc. a fee of 250,000 shares of Rule 144 stock for twelve (12) months of RedChip Visibility Program and six (6) months of investor awareness services. RedChip Visibility Program services include the preparation of the equity research report(s). The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. The equity research report(s) are not a recommendation of a solicitation to purchase or sell any security, nor do they constitute investment advice. Investor awareness services and programs are designed to help companies communicate their investment characteristics. These services may include investor conferences, digital and print distribution of AEMD investor-related materials or services, and radio programming. None of the profiles issued by RedChip Companies, Inc., constitutes a recommendation for any investor to purchase or sell any particular security or that any security is suitable for any investor. Any investor should determine whether a particular security is suitable based on the investor's objectives, other securities holdings, financial situation needs, and tax status. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein.
Contact:
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
research@redchip.com
http://www.redchip.com
To receive a complimentary copy of the RedChip Research Report for AEMD, please visit: http://www.redchip.com/about/aboutmain.asp?rid=357
To learn more about Aethlon Medical, Inc. visit http://www.redchip.com/visibility/investor.asp?symbol=AEMD
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida; with affiliate offices in Beijing, China; Paris, France; and Seoul, Korea. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(TM), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap TV(TM), Shareholder Intelligence, Social Media and Blogging Services, Webcasts, and RedChip Radio(TM). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp.
"Discovering Tomorrow's Blue Chips Today"(TM)
The RedChip Companies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2761
Disclosure
None of the reports issued by RedChip Companies, Inc., constitutes a recommendation for any investor to purchase or sell any particular security nor do they constitute investment advice. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Information contained in the research reports is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. Aethlon Medical, Inc. (AEMD) is a client of RedChip Companies, Inc. and of RedChip Visibility, a division of RedChip Companies. AEMD has agreed to pay RedChip Companies, Inc. a fee of 250,000 shares of Rule 144 stock for twelve (12) months of RedChip Visibility Program and six (6) months of investor awareness services. RedChip Visibility Program services include the preparation of the equity research report(s). The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. The equity research report(s) are not a recommendation of a solicitation to purchase or sell any security, nor do they constitute investment advice. Investor awareness services and programs are designed to help companies communicate their investment characteristics. These services may include investor conferences, digital and print distribution of AEMD investor-related materials or services, and radio programming. None of the profiles issued by RedChip Companies, Inc., constitutes a recommendation for any investor to purchase or sell any particular security or that any security is suitable for any investor. Any investor should determine whether a particular security is suitable based on the investor's objectives, other securities holdings, financial situation needs, and tax status. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein.
Contact:
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
research@redchip.com
http://www.redchip.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Tuesday, April 19, 2011
Defense and Security Stocks Trading Alert; Visualant, Inc. (OTCBB: VSUL), Northrop Grumman (NYSE: NOC), L-3 (NYSE: LLL), Lockheed Martin (NYSE: LMT)
Point Roberts , WA - April 19, 2011 - Investorideas.com, an investor research portal covering multiple stock sectors including defense and security stocks, presents a sector close up on defense and security stocks trading for April 19 th. Leading defense stocks showed gains in spite of pending budget cuts in the defense sector. Northrop Grumman (NYSE: NOC) was up on news it was awarded $77.9 Million for U.S. Army Air and Missile Defense Workstation Development and Support.
Sector Snapshot
Market Snapshot
Northrop Grumman Awarded $77.9 Million for U.S. Army Air and Missile Defense Workstation Development and Support
CARSON, Calif., April 19, 2011 -- The U.S. Army has awarded Northrop Grumman Corporation (NYSE:NOC - News) a $77.9 million contract to continue providing software development and lifecycle support for the Air and Missile Defense Workstation (AMDWS).
AMDWS provides a composite air defense picture to war fighters and air and missile defense planning and situational awareness capabilities throughout the Army.
Under the five-year AMDWS Block 4 contract, Northrop Grumman will continue development of enabling technologies to evolve AMDWS capabilities and provide engineering, implementation, test, site and training support.
Full news http://finance.yahoo.com/news/Northrop-Grumman-Awarded-779-pz-4053594991.html?x=0&.v=1
TransTech Systems, a Subsidiary of Visualant (OTCBB: VSUL), Unveils Private Labeling of Identification Badge Printer Bundles and Supply Kits
SEATTLE - April 19, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce the launch of private label badge printer bundles and supply kits in their product line.
Full news: http://www.investorideas.com/CO/VSUL/news/2011/04191.asp
Company Snapshot:
About Visualant, Inc. (OTCBB: VSUL)
Visit the company profile on Investorideas.com
http://www.investorideas.com/CO/VSUL/
Visualant, Inc. develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Its patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching (SPM). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner. www.visulant.net
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States. www.ttsys.com
Contact Visualant, Inc.
Lynn Felsinger, 206-903-1341
lynn@visualant.net
Investor RelationsCore Consulting Group
Paul DeRiso, 925-465-6088
paul@coreconsultingroup.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Defense and security portals:
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Disclaimer:
This news is paid for as part of the showcase advertising program for Visualant, Inc. (OTCBB: VSUL) Visualant is a featured showcase company on Investorideas.com, 1500 per month and $five thousand per month in restricted 144 shares. (UZZ>V- $500) Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information on showcase companies is taken from public documents, news, filings and the company website and management. This site is currently compensated by featured companies, news submissions and online advertising. Investors are reminded all investment involves risk including possible loss of principal.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Contact Investorideas.com
dvanzant@investorideas.com 800 665 0411
Sector Snapshot
- L-3 Communications Holdings, Inc (NYSE: LLL ) trading up at $75.5, up 0.58 (0.77%) 1:41PM EDT
- Lockheed Martin Corporation (NYSE: LMT ) trading up at $77.08, up 0.18 (0.23%) 1:55PM EDT
- Northrop Grumman (NYSE: NOC ) trading up at $60.61, up 0.19 (0.31%) 1:45PM EDT
- United Protection Security Group Inc. (TSX.V: UZZ) trading at $0.055- .06
- Visualant, Inc. (OTCBB: VSUL) trading at $0.45- 49 on news
Market Snapshot
- Dow 12,253.55 +51.96 +0.43%
- Nasdaq 2,740.97 +5.59 +0.20%
- S&P 500 1,310.60 +5.46 +0.42%
- 10 Yr Bond (%) 3.3650% -0.0060
- Oil 108.15 +0.83 +0.77%
- Gold 1,494.00 +1.70 +0.11%
Northrop Grumman Awarded $77.9 Million for U.S. Army Air and Missile Defense Workstation Development and Support
CARSON, Calif., April 19, 2011 -- The U.S. Army has awarded Northrop Grumman Corporation (NYSE:NOC - News) a $77.9 million contract to continue providing software development and lifecycle support for the Air and Missile Defense Workstation (AMDWS).
AMDWS provides a composite air defense picture to war fighters and air and missile defense planning and situational awareness capabilities throughout the Army.
Under the five-year AMDWS Block 4 contract, Northrop Grumman will continue development of enabling technologies to evolve AMDWS capabilities and provide engineering, implementation, test, site and training support.
Full news http://finance.yahoo.com/news/Northrop-Grumman-Awarded-779-pz-4053594991.html?x=0&.v=1
TransTech Systems, a Subsidiary of Visualant (OTCBB: VSUL), Unveils Private Labeling of Identification Badge Printer Bundles and Supply Kits
SEATTLE - April 19, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce the launch of private label badge printer bundles and supply kits in their product line.
Full news: http://www.investorideas.com/CO/VSUL/news/2011/04191.asp
Company Snapshot:
About Visualant, Inc. (OTCBB: VSUL)
Visit the company profile on Investorideas.com
http://www.investorideas.com/CO/VSUL/
Visualant, Inc. develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Its patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching (SPM). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner. www.visulant.net
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States. www.ttsys.com
Contact Visualant, Inc.
Lynn Felsinger, 206-903-1341
lynn@visualant.net
Investor RelationsCore Consulting Group
Paul DeRiso, 925-465-6088
paul@coreconsultingroup.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Defense and security portals:
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Disclaimer:
This news is paid for as part of the showcase advertising program for Visualant, Inc. (OTCBB: VSUL) Visualant is a featured showcase company on Investorideas.com, 1500 per month and $five thousand per month in restricted 144 shares. (UZZ>V- $500) Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information on showcase companies is taken from public documents, news, filings and the company website and management. This site is currently compensated by featured companies, news submissions and online advertising. Investors are reminded all investment involves risk including possible loss of principal.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Contact Investorideas.com
dvanzant@investorideas.com 800 665 0411
Security Stocks; TransTech Systems, a Subsidiary of Visualant (OTCBB:VSUL), Unveils Private Labeling of Identification Badge Printer Bundles and Supply Kits
SEATTLE - April 19, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce the launch of private label badge printer bundles and supply kits in their product line.
The new printer bundles include a badge printer and the necessary supplies to instantly print plastic cards in an all-in-one solution. Dealer-customized labels, packaging graphics, and box inserts are included with the bundles to enhance both post-sale service and simplify the reordering process for the end-user. As more shipments go direct to the end users for cost saving reasons, the identity of the local reseller is being lost. Customization of the packaging for the reseller creates a personalized and end user direct shippable solution. Direct shipping eliminates additional freight and handling costs, thus increasing dealers� overall margins. At the same time, the customized packaging maintains the reseller identity with the end user and preserves the recurring revenue for the reseller.
New printer supply kits include necessary printer ribbons, PVC cards, and cleaning components to print approximately 500 cards, varying by printer model. The kits are available for the industry�s most popular models of badge printers including HID�, Ultra Electronics�, and Evolis�. Dealer-customized packaging graphics and box inserts are also available, adding further value to the easy-to-order kits.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
The new printer bundles include a badge printer and the necessary supplies to instantly print plastic cards in an all-in-one solution. Dealer-customized labels, packaging graphics, and box inserts are included with the bundles to enhance both post-sale service and simplify the reordering process for the end-user. As more shipments go direct to the end users for cost saving reasons, the identity of the local reseller is being lost. Customization of the packaging for the reseller creates a personalized and end user direct shippable solution. Direct shipping eliminates additional freight and handling costs, thus increasing dealers� overall margins. At the same time, the customized packaging maintains the reseller identity with the end user and preserves the recurring revenue for the reseller.
New printer supply kits include necessary printer ribbons, PVC cards, and cleaning components to print approximately 500 cards, varying by printer model. The kits are available for the industry�s most popular models of badge printers including HID�, Ultra Electronics�, and Evolis�. Dealer-customized packaging graphics and box inserts are also available, adding further value to the easy-to-order kits.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)
Subscribe to:
Posts (Atom)